Explore tweets tagged as #PsyMed
The Future of Brain Drug Delivery Starts Here Listen to the full episode: https://t.co/vETP9CDYLw
0
0
0
Our observational study of psychedelic use in psychiatric prescribers is now in print #psychtwitter
0
7
18
Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions whole paper https://t.co/5J0EkDHEF6
5
6
34
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder | Psychedelic Medicine "no evidence of treatment emergent mania, hypomania or psychosis observed in any participants." https://t.co/NFM6iNMtqp
6
30
101
Happy to add to the conversation on psychedelics and plasticity with our new publication assessing the effects of DOI on hippocampal plasticity in an ex vivo model. Check it out!
3
6
28
Ibogaine analogue Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model - https://t.co/yveKUgLmXK
#ScholarAlerts
1
1
12
Getting into PsyMed in 2023 is like getting into crypto in 2013. Smart people accumulating in the space š
1
0
2
Our new study found perceived risk of LSD is dropping in US. Factors such as age, race, LSD use, being a sexual minority, and past yr suicide attempt were associated with perceived risk of LSD. ā¦@sdpnayakā© ā¦@drdarronsmithā© ā¦@JeremyWeleffā©
1
10
28
NEW EPISODE: "Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinsonās with Rob Malenka" Listen here:
We had Rob Malenka on the Business Trip podcast a couple years ago. Since then, heās gone from being full-time at Stanford to leading Google co-founderās philanthropic efforts in Parkinsonās, autism, and bipolar. One of my favorite convos yet. Link in comments.
0
0
2
Calling all entrepreneurial scientists! @PsymedVentures & @KdT_Ventures are co-hosting the 2nd annual Future Neuro Founders Program in October. If you're interested in building a neuro startup, sign up here: https://t.co/f4sJQjlz2X Speakers will be announced soon.
0
1
5
Just got back from MAPSā Psychedelic Science. A few reflections: The past few years have been of wild swings: ridiculous hype, then pure defeat. This year felt like things settled into grounding and humility. At PsyMed, we wrote most of our psychedelic checks a few years ago.
Our CEO and co-founder, Lucia Huang, spoke on a panel titled "Technology Across the Psychedelic Continuum" at Psychedelic Science 2025, the largest psychedelic conference of its kind. Joined by industry leaders Danielle Schlosser, PhD and Julie Friedman Simon,Ā moderated by
0
0
4
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research https://t.co/RWDDjBHTVp
2
1
3
š Whatās ahead for life science & healthcare investment in 2025? Join us Sept 4 at 12 PM ET for 2025 Investment Outlook: Active Perspectives from Investors & Strategic Partners featuring PsyMed Ventures, AstraZeneca & MEDA Ventures. š Register now https://t.co/KWjCWVQIRE
0
0
0
Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users https://t.co/LkysGUyBeX
7
12
43
Fund Mental Health Smarter With Mindful Philanthropy Listen to the full episode: https://t.co/OLGxrUZhZq
0
0
0
Cracking the Brain's Security System š§ š Listen to the full episode: https://t.co/vETP9CDYLw
0
0
1
#Journey #Clinical, a New York-based psychedelic therapy company, raised $8.5 million in funding. Union Square Ventures led the round and was joined by AlleyCorp, Fifty Years, Able Partners, Gaingels, Palo Santo, PsyMed Ventures, Coalition Operators, Mystic Ventures. #healthcare
0
0
0
Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers | Psychedelic Medicine
1
3
6